This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: July 12, 2026·Last reviewed: October 15, 2026·Prices re-read October 15, 2026 (rows marked)·Methodology v4.1

Researched By

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

NexLife vs Eden: pricing, doses and services compared

Which is better for whom?

NexLife and Eden serve different priorities. NexLife: compounded tirzepatide $169 month to month or $139 on a 12-month plan, same price at… Eden: Flat compounded pricing every month: $99 semaglutide or $129 tirzepatide, with “No membership fees”… There is no universal winner — the right choice depends on whether you optimize for lowest starter price, flat dose pricing, or bundled clinical services. Prices marked October 15, 2026 were re-read that day; other fields are from the July 12, 2026 review.

The $449 tier has a condition. LillyDirect prices Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) a month under its self-pay programme. The $449 rate on 7.5 mg and above holds only if you refill within 45 days of your previous delivery. Miss that window and the refill is charged at the standard rate — reported at $499 to $699 depending on dose — before the programme rate resumes on the next order. Re-read at source 4 August 2026.

How do they compare, field by field?

NexLife vs Eden — side by side; July 12, 2026 figures, with October 15, 2026 re-reads marked
Factor	NexLife	Eden
Starting price	$139/mo (tirzepatide, 12-month plan) Verified	$99 semaglutide; $129 tirzepatide, every month, read Oct 15 Re-read Oct 15 · changed
Renewal price	$169 month to month; $159 / $149 / $139 on 3-, 6-, 12-month plans Verified	$129 tirzepatide, every month Re-read Oct 15 · changed
Highest-dose price	Flat — no dose-based increase Verified	“No dose-based price hikes” Re-read Oct 15 · changed
Membership	$0 Verified	None (“No membership fees”) Re-read Oct 15 · changed
Labs	Not stated as included Verified	Pending research Reported — pending verification
Shipping	Included (expedited) Verified	Pending research Reported — pending verification
Commitment	12-month or month-to-month Verified	Monthly Reported — pending verification
Pharmacy	Plan pages name three 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) (licences not yet independently verified by us) Verified	Not independently verified Reported — pending verification
Clinician	Medical Director: Adam Kennah, M.D. (named on NexLife’s pages; NPI provider-supplied) Verified	Clinician network Reported — pending verification
States	All 50 states where its affiliated providers are licensed Verified	Pending research Reported — pending verification

Which one wins on each decision factor?

Each factor below is measured from the providers’ own pages read on October 15, 2026, and the numbers are shown so you can check them. Where one program wins every factor, it is because the other printed a higher price or no price at all; the limitations sections above still apply.

Winner by decision factor, from prices and pages read October 15, 2026
Decision factor	Better fit
Lower standing monthly price (lowest plan, Oct 15)	Eden ($129 vs $139)
Lower month-to-month price (Oct 15)	Eden ($129 vs $169)
Names its dispensing pharmacy on its pages	NexLife
States the same price at every dose	Both

NexLife: who it fits

NexLife sells compounded tirzepatide for $169 a month month to month, or $159, $149 and $139 a month on 3-, 6- and 12-month plans, at the same price for every dose and with no membership fee; compounded semaglutide is $139 to $119 a month on the same terms (nexlife.us, read October 15, 2026). Its plan pages list provider review, a nutrition plan, a 1:1 wellness-coach call, 24/7 support and free expedited shipping, and name three 503A pharmacies; lab work is not stated as included. Limitation: Eden publishes a lower month-to-month price ($129 tirzepatide, $99 semaglutide, no membership). NexLife offers no brand-name pathway and no insurance coordination, and its 12-month price requires a 12-month plan. Full NexLife review →

Eden: who it fits

Flat compounded pricing every month: $99 semaglutide or $129 tirzepatide, with “No membership fees” (read October 15, 2026). Limitation: Eden resells brand Zepbound at $1,399/month and brand Wegovy at $1,695/month. The manufacturers sell the identical drugs direct for $299–$449 and $149–$349. Check LillyDirect and NovoCare before buying brand through Eden. Full Eden review →

Frequently asked questions

Is NexLife or Eden cheaper?

On starting price: NexLife is $139/mo (tirzepatide, 12-month plan) and Eden is $99 semaglutide; $129 tirzepatide, every month, read Oct 15. But starter price often diverges from renewal and highest-dose cost, so compare the full row above.

How were these figures verified?

Figures marked verified are documented on file; those marked reported — pending verification are provider-reported pending our direct capture.

Sources

Both providers' pricing and terms pages, captured July 12, 2026.
Our price-normalization methodology.
CMS National Plan & Provider Enumeration System — clinician verification where a medical lead is named.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.